Rezáč A, Jílek P, Rezáčová V, Skapinec P, Sedláková I, Tošner J, Spaček J
Ceska Gynekol. 2013 Dec;78(6):514-21.
To analyze hypersensitivity reactions to carboplatin and paclitaxel in patients treated with systemic administration of chemotherapy (carboplatin and/or paclitaxel).
Retrospective study.
Department of Obstetrics and Gynecology, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove.
One hundred-forty patients treated with systemic administration of chemotherapy were enrolled to our study between years 2008 and 2012. The presence and the grade [grade (G) 1-5; 1 = moderate, 5 = death] of hypersensitivity reactions (HSRs) were evaluated, as well as the influence of some clinical parameters on development of HSR.
In total 29 HSRs in 21 patients were analyzed. To carboplatin were reported 19 (66%) HSRs: 13 (45%) HSRs of G1-G3 and 6 (21%) HSRs of G4. To paclitaxel were reported 10 (34%) HSRs: 9 (31%) HSRs of G1-G3 and 1 (3%) HSR of G4. The number of administered cycles of carboplatin to develop G1-G4 resp. G1-G3 HSR was higher in comparison with number of cycles to develop HSR of the same grade to paclitaxel(p = 0.001, resp. p = 0.01).
HSR to carboplatin is unlike paclitaxel affected by the number of administered cycles. This fact should be included in the clinical management of patients treated with intravenous chemotherapy using carboplatin.
分析接受全身化疗（卡铂和/或紫杉醇）的患者对卡铂和紫杉醇的过敏反应。
回顾性研究。
布拉格查理大学医学院妇产科及赫拉尼采大学医院。
2008年至2012年间，140例接受全身化疗的患者纳入本研究。评估过敏反应（HSR）的存在情况及分级[1 - 5级；1 = 中度，5 = 死亡]，以及一些临床参数对HSR发生的影响。
共分析了21例患者的29次HSR。报告对卡铂发生19次（66%）HSR：13次（45%）为1 - 3级HSR，6次（21%）为4级HSR。报告对紫杉醇发生10次（34%）HSR：9次（31%）为1 - 3级HSR，1次（3%）为4级HSR。发生1 - 4级及1 - 3级卡铂HSR的给药周期数高于发生相同分级紫杉醇HSR的周期数（分别为p = 0.001和p = 0.01）。
与紫杉醇不同，卡铂的HSR受给药周期数影响。这一事实应纳入使用卡铂进行静脉化疗患者的临床管理中。
